nach oben

Erschienen in:

2014 | OriginalPaper | Buchkapitel

19. Urothelkarzinom der Harnblase

verfasst von : T. Horn, J. Simon, J.E. Gschwend

Erschienen in: Facharztwissen Urologie

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Urothelkarzinome machen etwa 90% der Harnblasenkarzinome aus, der Rest entfällt auf Plattenepithel- und Adenokarzinome. Für ein Viertel der Harnblasenkarzinome sind Umweltfaktoren ursächlich, v. a der Zigarettenkonsum, daneben u. a. aromatische Amine, Cyclophosphamid, Phenacetin sowie eine Schistosomiasis. Die Mehrheit der Karzinome wird durch eine Hämaturie bemerkt. Für die Therapieentscheidung und Prognose sind verschiedene Scoresysteme zur Bewertung der Progressions- und Rezidivwahrscheinlichkeit entwickelt worden, am besten erscheinen hier derzeit die Risikotabellen des EORTC. Diagnostisch kommen neben bildgebenden Verfahren die Urinzytologie, Bestimmung von Urinmarkern sowie die Fluoreszenzdiagnostik zum Einsatz. Je nach Stadium sind die transurethrale Resektion der Blase, intravesikale Instillation von Chemo- oder Immuntherapeutika sowie der BCG-Prophylaxe, Radio-/Chemotherapie sowie radikalerer Operationsverfahren angezeigt. Entscheidend für die Lebensqualität des Patienten sind nach radikalem Eingriff die verschiedenen Optionen der Harnableitung bzw. des Harnblasenersatzes (z, B. Ileum- oder Kolonkonduit).

Andius P, Fehrling M, Holmang S (2005) Intravesical bacillus Calmette-Guerin therapy: experience with a reduced dwell-time in patients with pronounced side-effects. BJU Int 96(9): 1290–3PubMedCrossRef

Aveyard P, Adab P, Cheng KK, Wallace DM, Hey K, Murphy MF (2002) Does smoking status influence the prognosis of bladder cancer? A systematic review. BJU Int 90: 228PubMedCrossRef

Babjuk M, Oosterlinck W, Sylvester R et al. (2012) Guidelines on Non-muscle-invasive bladder cancer. Uroweb 2011. Available at: http://www.uroweb.org. Accessed January 2^nd, 2013

Babjuk M, Oosterlinck W, Sylvester R et al. (2011) EAU Guidelines on Non-Muscle–Invasive Urothelial Carcinoma of the Bladder, the 2011 Update. Eur Urol 59: 997–1008PubMedCrossRef

Bellmunt J, von der Maase H, Mead GM et al. (2007) Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study. J Clin Oncol, ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), LBA5030

Bellmunt Molins J, von der Maase HC, Theodore et al. (2008) Randomised phase III trial of vinflunine (V) plus best supportive care (B) vs B alone as 2nd line therapy after a platinum-containing regimen in advanced transitional cell carcinoma of the urothelium (TCCU). J Clin Oncol 26: abstr. 5028

Bellmunt J, Albiol S, Suarez C, Albanell J (2009) Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents. Crit Rev Oncol Hematol 69: 211PubMedCrossRef

Bohle A, Bock PR (2004) Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63: 682PubMedCrossRef

Boorjian SA, Kim SP, Weight CJ et al. (2011) Risk factors and outcomes of urethral recurrence following radical cystectomy. Eur Urol 60(6): 1266–72PubMedCrossRef

Botteman MF, Pashos CL, Redaelli A et al. (2003) The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21(18): 1315–30PubMedCrossRef

Calabro F, Sternberg CN (2008) Neoadjuvant and Adjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. Eur Urol 16: 16

Chang SS, Hassan JM, Cookson MS et al. (2003). Delaying radical cystectomy for muscle-invasive bladder cancer results in worse pathological stage. J Urol 170: 1085–7PubMedCrossRef

Chrouser K, Leibovich B, Bergstralh E et al. (2005) Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. J Urol 174(1): 107–10PubMedCrossRef

Dreicer R, Li S, Manola J et al. (2007) Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group. Cancer 110(4): 759–63PubMedCrossRef

Drieskens O, Oyen R, Van Poppel H et al. (2005) FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging 32(12): 1412–7PubMedCrossRef

Fradet Y, Grossman HB, Gomella L et al. (2007) A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 178(1): 68–73; discussion 73. (Epub 2007 May 11)

Garcia JA, Dreicer R (2006) Systemic chemotherapy for advanced bladder cancer: update and controversies. J Clin Oncol 24: 5545PubMedCrossRef

Gontero P, Bohle A, Malmstrom PU et al. (2010) The role of bacillus Calmette-Guerin in the Treatment of Non-Muscle-Invasive Bladder Cancer. Eur Urol 57: 410–29PubMedCrossRef

Gray Sears CL, Ward JF, Sears ST et al. (2002) Prospective comparison of computerized tomography and excretory urography in the initial evaluation of asymptomatic microhematuria. J Urol 168: 2457PubMedCrossRef

Grossman, H. B, Gomella, L, Fradet Y, et al. (2007) A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 178(1): 62–7PubMedCrossRef

Grossfeld GD, Litwin MS, Wolf JS et al. (2001) Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy-part I: definition, detection, prevalence and etiology. Urology 57: 599PubMedCrossRef

Gschwend JE, Fair WR, Vieweg J (2000) Radical cystectomy for invasive bladder cancer: contemporary results and remaining controversies. Eur Urol 38: 121PubMedCrossRef

Herr HW, Donat SM (1999) Prostatic tumor relapse in patients with superficial bladder tumors: 15-year outcome. J Urol 161: 1854PubMedCrossRef

Hussain MH, MacVicar GR, Petrylak DP et al. (2007) Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 25(16): 2218–24PubMedCrossRef

Jichlinski P, Guillou L, Karlsen SJ et al. (2003) Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer- a multicenter study. J Urol 170(1): 226–9PubMedCrossRef

Jocham D, Witjes F, Wagner S et al. (2005) Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 174(3): 862–6; discussion 866PubMedCrossRef

Kassouf W, Agarwal PK, Herr HW et al. (2008) Lympph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J Clin Oncol 26(1): 121–6PubMedCrossRef

Krege S, Rembrink V, Borgermann C et al. (2001) Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study. J Urol 165(1): 67–71PubMedCrossRef

Lamm DL, Blumenstein BA, Crissman JD et al. (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163: 1124PubMedCrossRef

Lehmann J, Suttmann H, Albers P et al. (2008) Surgery for Metastatic Urothelial Carcinoma with Curative Intent: The German Experience (AUO AB 30/05). Eur Urol 29: 29

Loehrer PJ Sr, Einhorn LH, Elson PJ et al. (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10(7): 1066–73PubMed

Logothetis CJ, Dexeus FH, Finn L et al. (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8(6): 1050–5PubMed

Lopez-Beltran A, Montironi R (2004) Non-invasive urothelial neoplasms: according to the most recent WHO classification. Eur Urol 46: 170PubMedCrossRef

Malmström PU, Sylvester RJ, Crawford DE et al. (2009) An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette Guerin for non-muscle-invasive bladder cancer. European Urology 56(2): 247–56PubMedCrossRef

Matsumoto K, Irie A, Satoh T et al. (2007) Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma. Int J Urol 14(11): 1000–4; discussion 1004PubMedCrossRef

Meluch AA, Greco FA, Burris HA 3rd et al. (2001) Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol 19(12): 3018–24PubMed

Mills RD, Studer UE (1999) Metabolic consequences of continent urinary diversion. J Urol 161: 1057PubMedCrossRef

Negri E, La Vecchia C (2001) Epidemiology and prevention of bladder cancer. Eur J Cancer Prev 10: 7PubMedCrossRef

O’Connor OJ, McSweeney SE, Maher MM (2008) Imaging of hematuria. Radiol Clin North Am 46: 113PubMedCrossRef

Okamura K, Ono Y, Kinukawa T et al. (2002) Randomized study of single early instillation of (2"R)-4’-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma. Cancer 94(9): 2363–8PubMedCrossRef

Palou J, Rodriguez-Rubio F, Huguet J et al. (2005) Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. J Urol 174(3): 859–61PubMedCrossRef

Raj GV, Bochner BH (2007) Radical cystectomy and lymphadenectomy for invasive bladder cancer: towards the evolution of an optimal surgical standard. Semin Oncol 34: 110PubMedCrossRef

Robert Koch-Institut und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V., Hrsg. (2012) Krebs in Deutschland 2007/2008. 8. Ausgabe, Berlin

Rodel C, Grabenbauer GG, Kuhn R et al. (2002) Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 20(14): 3061–71PubMedCrossRef

Saksena MA, Dahl DM, Harisinghani MG (2006) New imaging modalities in bladder cancer. World J Urol 24: 473PubMedCrossRef

Schmidbauer J, Witjes F, Schmeller N et al. (2004) Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 171(1): 135–8PubMedCrossRef

Shelley MD, Barber J, Wilt T et al. (2002) Surgery versus radiotherapy for muscle-invasive bladder cancer. Cochrane Database Syst Rev (1):CD002079

Shipley WU, Kaufman DS, Zehr E et al. (2002) Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 60(1): 62–7; discussion 67–8PubMedCrossRef

Sobin LH, Gospodarowicz MK, Wittekind C, eds. (2009) TNM classification of malignant tumors (UICC International Union Against Cancer). Ed 7. New York, NY:Wiley-Blackwell: 262–5

Solsona E, Iborra I, Ricos JV et al (1995) The prostate involvement as prognostic factor in patients with superficial bladder tumors. J Urol 154(5): 1710–13PubMedCrossRef

Sonpavde G, Ross R, Powles T et al. (2008) Novel agents for muscle-invasive and advanced urothelial cancer. BJU Int 101: 937PubMedCrossRef

Stadler WM, Kuzel T, Roth B et al. (1997) Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15(11): 3394–8PubMed

Stein JP, Penson DF, Wu SD, Skinner DG (2007) Pathological guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the literature. J Urol 178: 756PubMedCrossRef

Stein JP, Lieskovsky G, Cote R et al. (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 19(3): 666–75PubMed

Stein JP, Clark P, Miranda G et al. (2005) Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients. J Urol 173: 1163–8PubMedCrossRef

Stenzl A, Jocham D, Jichlinski P, Junker K, Konig F, van den Bergh H et al. (2008) Photodynamic diagnostics in the urinary tract. Consensus paper of the Working Group for Oncology of the German Society for Urology. Urologe A 47: 982PubMedCrossRef

Stenzl A, Witjes JA, Comperat E et al. (2012) Guidelines on Bladder Cancer Muscle-invasive and Metastatic. Uroweb 2011. Available at: http://www.uroweb.org. Accessed January 2^nd, 2013

Stenzl, Burger M, Fradet Y et al. (2010) Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol 184(5): 1907–13PubMedCrossRef

Stenzl A, Cowan NC, De Santis M et al. (2011) Treatment of Muscle-Invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines. Eur Urol 59: 1009–18PubMedCrossRef

Sternberg CN, de Mulder PH, Schornagel JH et al. (2001) Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19(10): 2638–46PubMed

Sternberg CN, Donat SM, Bellmunt J et al. (2007) Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 69: 62PubMedCrossRef

Suttmann H, Kamradt J, Becker F, Lehmann J, Stockle M (2009) [Extending the limits of lymphadenectomy during radical cystectomy : Pitfalls in the interpretation of contemporary study results.]. Urologe A 48: 151PubMedCrossRef

Sylvester RJ, van der Meijden AP, Oosterlinck W et al. (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49: 466PubMedCrossRef

Sylvester RJ, Oosterlinck W, Witjes JA (2008) The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol 53: 709PubMedCentralPubMedCrossRef

Uhm JE, Lim HY, Kim WS et al. (2007) Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract. Neoplasia 9(1): 18–22PubMedCentralPubMedCrossRef

Van Rhijn BWG, van der Kwast TH, Alkhateeb SS et al. (2012) A New and Highly Prognostic System to Discern T1 Bladder Cancer Substage. Eur Urol 61(2): 378–84PubMedCrossRef

Vaughn DJ, Broome CM, Hussain M et al. (2002) Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 20(4): 937–40PubMedCrossRef

von der Maase H, Hansen SW, Roberts JT et al. (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18(17): 3068–77

von der Maase H, Sengelov L, Roberts JT et al. (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23(21): 4602–8PubMedCrossRef

Titel: Urothelkarzinom der Harnblase
verfasst von: T. Horn
J. Simon
J.E. Gschwend
Verlag: Springer Berlin Heidelberg
Buch: Facharztwissen Urologie
Print ISBN: 978-3-642-44941-3

Electronic ISBN: 978-3-642-44942-0

Copyright-Jahr: 2014
DOI: https://doi.org/10.1007/978-3-642-44942-0_19

Neu im Fachgebiet Urologie

25.04.2024 | Nierenkarzinom | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

19. Urothelkarzinom der Harnblase

Zusammenfassung

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie